CHUM

Gyeonggi Content Agency to promote Gyeonggi Province videos and story IP-based content companies at the "2023 Singapore ATF"

Retrieved on: 
Thursday, November 23, 2023
CHUM, Best, Animation, ACCESS, Plant, MIPCOM, Convention center, Exhibition, ATF, Film industry, Pororo the Little Penguin, Gyeonggi Province, ICONIX

SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ -- Gyeonggi Province and the Gyeonggi Content Agency will be establishing a Gyeonggi Province Pavilion at the '2023 Singapore ATF(Asia TV Forum & Market)', Asia's largest digital content exhibition, to support nine animation and story IP-based content companies from Gyeonggi Province.

Key Points: 
  • SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ -- Gyeonggi Province and the Gyeonggi Content Agency will be establishing a Gyeonggi Province Pavilion at the '2023 Singapore ATF(Asia TV Forum & Market)', Asia's largest digital content exhibition, to support nine animation and story IP-based content companies from Gyeonggi Province.
  • The nine companies that will be participating in the 2023 Singapore ATF Gyeonggi Province Pavilion are WHYJ CONTENTS (Dinoman), ACCESS KOREA (SauceRia), PIXTREND (Guardians), CHUM EDUCATION (Hattung Science), ICONIX (Pororo), HEYRANG PRODUCTION (Galls on Plants), STUDIO W.BABA.
  • ATF is a digital content exhibition in which more than 760 content/broadcasting companies from around the world participate every year.
  • In 2024, the Gyeonggi Content Agency will continue to participate in joint domestic and international exhibitions, and hold export consultations and educational seminars in order to help companies in Gyeonggi Province advance overseas, and will continue to provide support to promote the excellent contents of Gyeonggi Province to the world.

Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients

Retrieved on: 
Tuesday, November 21, 2023
Associate professor, CTRL, Prevalence, CHUM, Randomized controlled trial, CONTINUUM, American Heart Association, Disease, Risk, Smartphone, Patient, Heart failure, NYHA, Therapy, Digital, Standard of care, University, Diagnosis, INT, Quality of life, Hospital, Vital signs, Pharmaceutical industry

A self-care app via smartphone or tablet where patients entered vital signs, weight, and heart failure symptoms; 2.

Key Points: 
  • A self-care app via smartphone or tablet where patients entered vital signs, weight, and heart failure symptoms; 2.
  • Digital therapeutics automated medication suggestions sent to the treating medical team; and 4.
  • Heart failure educational modules for patients – all based on Greybox Solutions' Takecare platform.
  • Preliminary results are available for the first 63 patients that completed the study, 32 intervention (INT) and 31 control (CTRL).

New CRISPR/Cas9 Licensing Agreement for ERS Genomics & CHUM Research Centre, Montreal

Retrieved on: 
Thursday, October 26, 2023
Gene editing, Research, ERS, Genomics, Cas9, Biotechnology, Acquisition, Growth, Science, University, Nobel Prize, CHUM, Collection, Pharmaceutical industry

DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with the CHUM Research Centre ('(CRCHUM),'). This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with the CHUM Research Centre ('(CRCHUM),').
  • This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio.
  • Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The CHUM Research Centre is the largest research centre in the field of biomedical sciences and health care at the University of Montreal.

New CRISPR/Cas9 Licensing Agreement for ERS Genomics & CHUM Research Centre, Montreal

Retrieved on: 
Thursday, October 26, 2023
Gene editing, Research, ERS, Genomics, Cas9, Biotechnology, Acquisition, Growth, Science, University, Nobel Prize, CHUM, Collection, Pharmaceutical industry

DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with the CHUM Research Centre ('(CRCHUM),'). This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio. 

Key Points: 
  • DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with the CHUM Research Centre ('(CRCHUM),').
  • This is a non-exclusive licensing agreement granting the CRCHUM research rights to the ERS CRISPR/Cas9 patent portfolio.
  • Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
  • The CHUM Research Centre is the largest research centre in the field of biomedical sciences and health care at the University of Montreal.

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

Retrieved on: 
Monday, October 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, OSE, MTD, HCC, Mnemos EP, ESMO, ISIN, Human, European Society for Medical Oncology, CD47, HNSCC, Hackensack Meridian Health, Boehringer Ingelheim, Centre hospitalier, Clinical trial, Immunoglobulin G, Partnership, Oncology, Tumor microenvironment, Hackensack University Medical Center, Cancer, Hepatocellular carcinoma, CHUM, Patient, Mab, Myelocyte, Vaccine, Fine chemical, Pharmaceutical industry, QC

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).
  • BI 770371 is an IgG1 mAb that recognizes both the V1 and V2 variants of SIRPα.
  • We are very pleased to potentially make our selective SIRPα inhibitor technology available to more patients through this strategic collaboration.
  • The first clinical results of BI 770371 presented at ESMO 2023 conference (Madrid, Abstract #697P ) showed that adverse events were manageable during the on-treatment period, Maximal Tolerated Dose (MTD) has not been reached.

CDPQ takes part in bond financing for new Île-aux-Tourtes bridge

Retrieved on: 
Monday, June 12, 2023
Samuel, CHUM, CDPQ, Wind, Seignory, Investment, Vaudreuil-Soulanges Regional County Municipality, Farm, REM, Renewable energy, Boralex

"Financing the new Île-aux-Tourtes bridge is another opportunity for CDPQ to demonstrate its capacity to leverage various financial tools to support transformative projects in Greater Montréal and across Québec," said Marc Cormier, Executive Vice-President and Head of Fixed Income at CDPQ.

Key Points: 
  • "Financing the new Île-aux-Tourtes bridge is another opportunity for CDPQ to demonstrate its capacity to leverage various financial tools to support transformative projects in Greater Montréal and across Québec," said Marc Cormier, Executive Vice-President and Head of Fixed Income at CDPQ.
  • "We are delighted to participate in the financing of this essential infrastructure.
  • Rebuilding the bridge will ensure the mobility of people and goods while favouring active and public transportation."
  • CDPQ's infrastructure investments also include various wind farms, including the Seigneurie de Beaupré, one of Canada's largest wind farms, via its interests in Boralex and Énergir.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Retrieved on: 
Monday, June 5, 2023
Allosteric regulation, Failure, G protein-coupled receptor, CHUM, Centre hospitalier, Cancer, PAR2, GABAA receptor negative allosteric modulator, Research, CAF, NAM, Immunotherapy, Fibrosis, GPCR, Patient, Neoplasm, EP4, Therapy, Immunosuppression, Gq alpha subunit, Pharmaceutical industry, Vaccine

Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.

Key Points: 
  • Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.
  • PAR2 is a novel therapeutic target in oncology and immuno-oncology, involved in several processes such as tumor proliferation, resistance to immunotherapy and fibrosis.
  • Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The nomination of our first-in-class PAR2 NAM drug candidate, DT-9045, is an exciting step forward for Domain Therapeutics and for cancer treatment in general.

Scotiabank donates $1.35M to the MUHC Foundation to create a Montreal without hepatitis C

Retrieved on: 
Thursday, May 11, 2023
Infection, McGill University Health Centre, Partnership, Jewish General Hospital, HIV, Homelessness, Public, CHUM, Policy, Communication, MUHC, Prisoner, Chief sustainability officer, Scar, Lawyer, Life expectancy, Hepatitis C, Sterilization, Judgement, Social, Instrument, Conditional sentence, Division, Patient, Risk, Refugee, General Hospital, McGill University, Liver, City, Health, SVP, Cirrhosis, HCV, Disease, Vaccine, Nursing, Medical device, Scotiabank, Medicine

A new $1.35 million gift from Scotiabank to the McGill University Health Centre (MUHC) Foundation is helping to fund Montréal sans HépC, an innovative new program that aims to eliminate hepatitis C in Montreal through community-based advocacy and health care.

Key Points: 
  • A new $1.35 million gift from Scotiabank to the McGill University Health Centre (MUHC) Foundation is helping to fund Montréal sans HépC, an innovative new program that aims to eliminate hepatitis C in Montreal through community-based advocacy and health care.
  • Hepatitis C is curable—and curing Hepatitis C contributes to reducing transmission, a key element to HCV elimination.”
    Montréal sans HépC has partnered with the Centre associatif polyvalent d’aide hépatite C (CAPHAC) to reach people living with hepatitis C in their own communities.
  • We are grateful to Scotiabank for its generous gift.”
    “The stigma surrounding hepatitis C means thousands of individuals don’t receive the care they need.
  • Their concerted efforts will leave no hiding place, no lurking reservoir of infections left for hepatitis C in Montreal.

IntraOp Medical Corporation Announces Their 10th Mobetron with FLASH-IQ Installation Worldwide

Retrieved on: 
Thursday, May 11, 2023
Radiology, Biotechnology, Oncology, General Health, Health, Medical Devices, Hospitals, Health Technology, University, Intraoperative electron radiation therapy, CHUM, Cancer, Research, University of Wisconsin Carbone Cancer Center, Sale, CHUV, University of Lausanne, MD Anderson Cancer Center, Radiation therapy, Radiation, FLASH, Patient, NMSC, Ultra, Growth, Ides, Lausanne University Hospital, Pharmaceutical industry, Nightclub

IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.

Key Points: 
  • IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.
  • IntraOp Mobetron with FLASH-IQ is a novel radiotherapy platform capable of delivering an Ultra-High Dose Rate (UHDR) electron beam.
  • Several additional sites are applying for IDEs in the US, along with Canada, Belgium and Germany applying for similar exemptions in their countries.
  • IntraOp supports these applications and looks forward to the continued growth and development in the study of FLASH radiotherapy.

ALS Canada and Brain Canada invest more than $1.4 million in ALS research grants

Retrieved on: 
Wednesday, March 22, 2023
Human, Partnership, ALS Society of Canada, University, Western University, Memorial University of Newfoundland, Disability, CHUM, 3D, IRCM, Quality of life, G3BP1, Research, Neuro-ophthalmology, Biomarker, Antibody, University of Manitoba, DSM-IV codes, Person, Brain cell, Montreal Neurological Institute and Hospital, Barrow Neurological Institute, HIV disease progression rates, McGill University, Local government in Canada, Diagnosis, SLA, Health Canada, ALS, Pharmaceutical industry, Medical device

TORONTO, March 22, 2023 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are joining forces to invest in cutting-edge discoveries and treatments for amyotrophic lateral sclerosis (ALS).

Key Points: 
  • TORONTO, March 22, 2023 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are joining forces to invest in cutting-edge discoveries and treatments for amyotrophic lateral sclerosis (ALS).
  • Funding for one Discovery Grant was made possible by the Dr. Jean-Pierre Canuel Fund – SLA Québec, who generously contributed $150,000 to ALS Canada, which was matched by Brain Canada through the Canada Brain Research Fund (CBRF).
  • The CBRF is an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada Foundation, which increases Canadians’ support for brain research and expands the philanthropic space for funding brain research to achieve maximum impact.
  • To date, Health Canada has invested more than $145 million in brain research through the CBRF which has been matched by Brain Canada Foundation and its donors and partners.